Skip to content
February 14, 2017
In the News
Oramed CEO Nadav Kidron on CNBC: Oral insulin to be a gamechanger
Oral insulin to be a game changer: Oramed CEO Nadav Kidron tells CNBC
On Squawk Box Asia, Kidron t
alks about the company’s latest offering
Prev
Previous
BioTuesdays: Oramed hopes to start Phase 3 oral insulin trial next year
Next
Bloomberg: Oramed Plans Secondary Listing in Tel Aviv Soon, CEO Nadav Kidron Says
Next
You may also be interested
Oramed Launches Oral Insulin Safety Trial
July 9, 2013
In the News
Forbes: Oral Covid Vaccine Set To Begin Trials In Israel
August 30, 2021
In the News
Biopharma Dive: Oramed’s oral insulin shines in mid-stage trials
May 24, 2016
In the News
Join our mailing list
Email
SUBSCRIBE
+1-844-9-ORAMED
office@oramed.com
Linkedin-in
Facebook-f
Twitter
Youtube
Home
About
Technology
Pipeline
Video Library
Contact us
NEWS
Press Releases
In the News
Scientific Articles and Abstracts
Events & Presentations
INVESTORS
Corporate presentation
Annual shareholder meeting
Investor Relations
SEC filings
Investor FAQ
Governance documents
Investor tools
Oravax Medical
Skip to content
Open toolbar
Accessibility Tools
Accessibility Tools
Increase Text
Increase Text
Decrease Text
Decrease Text
Grayscale
Grayscale
High Contrast
High Contrast
Negative Contrast
Negative Contrast
Light Background
Light Background
Links Underline
Links Underline
Readable Font
Readable Font
Reset
Reset
